To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

J.P. Morgan analyst Lisa Gill maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $54.03. Gill covers the ...

CVS Health shows signs of recovery and growth potential. Learn why CVS stock is a buy with improved cash flow and strong ...

CVS Health (CVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz ...

CVS Health fell short on third-quarter profit, but it posted strong sales and the health care giant shook up leadership under ...

CVS expects elevated medical costs to continue to pressure its performance this year, “and as a result we are not providing a ...

Here is a list of many popular retailers that are confirmed to be open on Veterans Day 2024, along with their store hours, ...

The news lifted the stock Wednesday. Revenue was lifted by jumps in sales at the firm's Pharmacy & Wellness and Health Care Benefits segments. CVS also shook up its executive lineup, adding former ...

Our expert, award-winning staff selects the products we cover and rigorously researches and tests our top picks. If you buy through our links, we may get a commission. Reviews ethics statement ...

CVS Health fell short on third-quarter profit, but it posted strong sales and the health care giant ... will lead CVS Caremark, CVS Pharmacy, and the company’s Health Care Delivery businesses.